TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28314755

Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation for 12 months; increased monthly until SU <6 mg/dL.
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group continuing current dose of allopurinol.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation group.
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 183
Study: 26669202

Group type: EXPERIMENTAL
Intervention: Santong needling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Jingjin puncture)
Number of subjects: 60
Study: 24456367

Group type: EXPERIMENTAL
Intervention: Korean traditional diet (KTD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (eat as usual)
Number of subjects: 41
Study: 22232085

Group type: EXPERIMENTAL
Intervention: Pregabalin (300-450 mg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 19916994

Group type: EXPERIMENTAL
Intervention: Individualized dosing of enoxaparin
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional dosing of enoxaparin
Number of subjects: 118
Study: 17290026

Group type: EXPERIMENTAL
Intervention: recombinant activated factor VII (rFVIIa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 15065473

Group type: COMPARATOR
Intervention: Decisional Control group
Number of subjects: 102

Group type: COMPARATOR
Intervention: No‐Decisional Control group
Number of subjects: 102

Group type: COMPARATOR
Intervention: Treatment as Usual Control group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Interpersonal appraisals (Impact Message Inventory)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oppressive interpersonal impacts (physician low friendliness, patient low friendliness, high dominance, high hostility)
Number of subjects: 102
Study: 11320542

Group type: EXPERIMENTAL
Intervention: NSAID administered 3 doses during 24 hours before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered
Number of subjects: 60
Study: 9205582

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra-articular local anaesthetic
Number of subjects: 20
Study: 7907668

Group type: EXPERIMENTAL
Intervention: Deliberate increase of oxygen delivery index to greater than 600 mL/min per square meter using dopexamine hydrochloride infusion
Number of subjects: 107

Group type: COMPARATOR
Intervention: Best standard perioperative care
Number of subjects: 107
Study: 2877912

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg h.s.
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg b.i.d.
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg b.i.d.
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study: 29522362

Group type: EXPERIMENTAL
Intervention: ADT+D (androgen deprivation therapy with docetaxel)
Number of subjects: 790

Group type: COMPARATOR
Intervention: ADT (androgen deprivation therapy alone)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: ADT+D
Number of subjects: 790

Group type: COMPARATOR
Intervention: ADT
Number of subjects: 790
Study: 27509064

Group type: EXPERIMENTAL
Intervention: Experimental automation-assisted approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard protocols and equipment (Control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 25327918

Group type: EXPERIMENTAL
Intervention: Conjunctival auto-graft (n=26)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conjunctival rotation flap (n=31)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Conjunctival auto-graft and Conjunctival rotation flap
Number of subjects: 57
Study: 23491524

Group type: EXPERIMENTAL
Intervention: 90 mg ticagrelor twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10 mg prasugrel once daily
Number of subjects: 30
Study: 20973462

Group type: EXPERIMENTAL
Intervention: Quality Protein Maize (QPM)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Conventional maize
Number of subjects: 362
Study: 18494750

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0
Study: 16707975

Group type: EXPERIMENTAL
Intervention: Pancreatic sphincterotomy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dual sphincterotomy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Prophylactic pancreatic stenting
Number of subjects: 11
Study: 12502975

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 60% oxygen
Number of subjects: 36
Study: 10755205

Group type: EXPERIMENTAL
Intervention: Rescue thrombolysis with rTPA 50 mg (10 mg bolus + 40 mg in 60 minutes)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rescue thrombolysis with rTPA
Number of subjects: 90
Study: 9103739

Group type: EXPERIMENTAL
Intervention: Parent training treatment group (PT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Child training group (CT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Combined child and parent training group (CT + PT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waiting-list control group (CON)
Number of subjects: 97
Study: 8466094

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 0
Study: 3003317

Group type: EXPERIMENTAL
Intervention: Bicarbonate-containing oral rehydration solution
Number of subjects: 97

Group type: COMPARATOR
Intervention: Citrate-containing oral rehydration solution
Number of subjects: 97
Study: 31764959

Group type: EXPERIMENTAL
Intervention: Lanabecestat 20 mg
Number of subjects: 2218

Group type: EXPERIMENTAL
Intervention: Lanabecestat 50 mg
Number of subjects: 2218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2218
Study: 31152876

Group type: EXPERIMENTAL
Intervention: Methylene blue in surfactant vehicle with 5 min irradiation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aqueous methylene blue‐mediated PDT
Number of subjects: 30
Study: 28367952

Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation (2.5 mg/d folic acid, 50 mg/d vitamin B6, 1 mg/d vitamin B12)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25682480

Group type: EXPERIMENTAL
Intervention: Quetiapine (400mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 60
Study: 23692616

Group type: EXPERIMENTAL
Intervention: NIV (16 cmH2O IPS and 5 cmH2O PEEP) plus HOx (FiO2 = 0.4)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham NIV (7 cmH2O IPS and 5 cmH2O PEEP) plus HOx
Number of subjects: 13
Study: 22014760

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Soother (Control)
Number of subjects: 57
Study: 19852814

Group type: EXPERIMENTAL
Intervention: 800 microgram of misoprostol
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 16500387

Group type: EXPERIMENTAL
Intervention: Transduodenal radial EUS of the biliary tree
Number of subjects: 95
Study: 14980920

Group type: EXPERIMENTAL
Intervention: Ampofol (lower-lipid emulsion of propofol)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Diprivan (standard propofol emulsion)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ampofol
Number of subjects: 63

Group type: COMPARATOR
Intervention: Diprivan
Number of subjects: 63
Study: 11729795

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study: 9754894

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin) with or without TED stockings
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 8132702

Group type: EXPERIMENTAL
Intervention: 100 mg coumarin and cimetidine daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3 g coumarin daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 g coumarin daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3043033

Group type: EXPERIMENTAL
Intervention: Cefbuperazone (CBPZ) 4 g/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cefbuperazone (CBPZ) 2 g/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cefbuperazone (CBPZ)
Number of subjects: 32
Study: 1473409

Group type: EXPERIMENTAL
Intervention: Oral gentamicin and metronidazole for two days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined (oral + i.v.) gentamicin and metronidazole
Number of subjects: 16
Study: 54578

Group type: EXPERIMENTAL
Intervention: Oral disopyramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31013235

Group type: EXPERIMENTAL
Intervention: DARSI program (Developing Healthy and Egalitarian Adolescent Relationships)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control groups (2 control groups)
Number of subjects: 191
Study: 28122555

Group type: EXPERIMENTAL
Intervention: Deployment of trained community reproductive nurses (CORN) in health centres (arm 1)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Deployment of trained community reproductive nurses (CORN) in community/health posts (arm 2)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control villages without the intervention (arm 3)
Number of subjects: 282
Study: 26047892

Group type: EXPERIMENTAL
Intervention: Esmirtazapine 3.0 mg
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Esmirtazapine 4.5 mg
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Esmirtazapine (both doses)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Number of subjects: 419
Study: 23583010

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 21451509

Group type: EXPERIMENTAL
Intervention: CCX354 100 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCX354 300 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCX354 1-300 mg/day oral doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19944874

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 186
Study: 16622646

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (600 mg/day during chemotherapy and 3 months after cessation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no vitamin E supplementation)
Number of subjects: 30
Study: 15228804

Group type: EXPERIMENTAL
Intervention: robot training plus conventional therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 56
Study: 11264915

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Progressive muscle relaxation
Number of subjects: 24
Study: 9886157

Group type: EXPERIMENTAL
Intervention: Carbon monoxide (3.9%) exposure at sea level
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Simulated high-altitude clean air exposure
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sea-level carbon monoxide exposure
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Joint exposure to carbon monoxide at simulated high altitude
Number of subjects: 17

Group type: COMPARATOR
Intervention: Simulated high altitude
Number of subjects: 17
Study: 8002849

Group type: EXPERIMENTAL
Intervention: Low cholesterol levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cholesterol-lowering strategies
Number of subjects: 0
Study: 2927483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160 mg and 800 mg, given orally four times a day for 10 days, then 160 mg and 800 mg three times a week)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sulfadoxine and pyrimethamine (500 mg and 25 mg weekly)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prophylactic regimen (trimethoprim-sulfamethoxazole or sulfadoxine-pyrimethamine)
Number of subjects: 32
Study: 30729418

Group type: EXPERIMENTAL
Intervention: Intervention (LS screening)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 194
Study: 28369942

Group type: EXPERIMENTAL
Intervention: Operator knew fetal spine position (Group B)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Operator did not know fetal spine position (Group A)
Number of subjects: 58
Study: 24689695

Group type: EXPERIMENTAL
Intervention: Nurse-guided, basal-prandial insulin treatment protocol (NGP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Physician-guided therapy (PGT)
Number of subjects: 53
Study: 23375931

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) for 15 min
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (antishock trousers deflated)
Number of subjects: 28
Study: 21401358

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 18 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no omeprazole)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Omeprazole group
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 93
Study: 18481292

Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Nonsurgical cardiac comparison
Number of subjects: 244
Study: 16571155

Group type: EXPERIMENTAL
Intervention: 3 g/d of trans-11-18:1 (tVA) and 3 g/d of trans-12-18:1 (t12)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 0
Study: 12846896

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (r‐EPO) at a single, weekly dose of 40,000 U for at least 8 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (r‐EPO)
Number of subjects: 13
Study: 11232746

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg/day)
Number of subjects: 0
Study: 9506336

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Aspirin (250 mg/day)
Number of subjects: 41
Study: 7528126

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs in add-on trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in add-on trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs in monotherapy designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic failure criteria
Number of subjects: 0
Study: 3164788

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study: 30702538

Group type: EXPERIMENTAL
Intervention: Individualized opioid dosing protocol for VOE management
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Weight-based opioid dosing protocol for VOE management
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Individualized protocol
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual ED strategy
Number of subjects: 236
Study: 28770894

Group type: EXPERIMENTAL
Intervention: Body Weight Support (BWS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Body Weight Support (no-BWS)
Number of subjects: 0
Study: 25692556

Group type: EXPERIMENTAL
Intervention: 6 mm long implants (test group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 10 mm long implants (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both 6 mm and 10 mm implants
Number of subjects: 45
Study: 25222614

Group type: EXPERIMENTAL
Intervention: 3-step early intervention program (at 33 and 42 weeks after conception and at 4 months' corrected age)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 22343119

Group type: EXPERIMENTAL
Intervention: Immediate-postoperative isophane insulin for evening blood glucose ≥140 mg/dl
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard-of-care control group (short-acting insulin and/or oral antidiabetic agents for blood glucose ≥180-250 mg/dl)
Number of subjects: 50
Study: 19587321

Group type: EXPERIMENTAL
Intervention: Spastic-paretic motoneurons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower-threshold motor units in spastic-paretic muscles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower-threshold motor units in contralateral muscles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower-threshold motor units in healthy control muscles
Number of subjects: 0
Study: 17503748

Group type: EXPERIMENTAL
Intervention: AI system for estimating drug exposure and interpreting pharmacokinetic data for LPV
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: AI system for estimating drug exposure and interpreting pharmacokinetic data for EFV
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: AI system recommendations for LPV
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: AI system recommendations for EFV
Number of subjects: 199
Study: 15355822

Group type: EXPERIMENTAL
Intervention: Clarithromycin 1g/day for 14 days
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 113
Study: 11592603

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (9 million units three times per week) and lamivudine (100 mg/daily) for 24 weeks
Number of subjects: 151

Group type: COMPARATOR
Intervention: Lamivudine (100 mg/daily) for 52 weeks
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b and lamivudine combination therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 151
Study: 9538976

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Human regular insulin (HR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin lispro (LP) and Human regular insulin (HR)
Number of subjects: 10
Study: 7628184

Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2116086

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium (0.6 mg/kg per day in four intravenous doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous saline placebo
Number of subjects: 80
Study: 323387

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 24

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 24
Study: 30578048

Group type: EXPERIMENTAL
Intervention: RECELL treatment (combined with widely meshed STSG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control treatment (standard meshed STSG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RECELL treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RECELL treatment and Control treatment
Number of subjects: 30
Study: 28012692

Group type: EXPERIMENTAL
Intervention: Coffee intake with 89 mg CGA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Coffee intake with 310 mg CGA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Purified 5-CQA (450 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 39
Study: 25549166

Group type: EXPERIMENTAL
Intervention: ITE EMHP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OTE EMHP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open-ear
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-training EMHP
Number of subjects: 12
Study: 23981511

Group type: EXPERIMENTAL
Intervention: Minocycline (25-100 mg daily based on weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21467563

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (n = 25)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Continuous posterior lumbar plexus block (n = 22)
Number of subjects: 47
Study: 20137620

Group type: EXPERIMENTAL
Intervention: Zenapax (induction therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular immunosuppressive therapy (control group)
Number of subjects: 30
Study: 18090877

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 11
Study: 15012174

Group type: EXPERIMENTAL
Intervention: Oral cyclosporin (CsA) with mycophenolate mofetil (2g daily) and prednisone (0.5-1 mg/kg daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Bayesian predictive performance for the model developed
Number of subjects: 67
Study: 11404230

Group type: EXPERIMENTAL
Intervention: Gaboxadol (15 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9715183

Group type: EXPERIMENTAL
Intervention: I:E ratio of 1:1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: I:E ratio of 3:1
Number of subjects: 8
Study: 9331118

Group type: EXPERIMENTAL
Intervention: Neoadjuvant paclitaxel (200 mg/m2/3 hour, day 1) and carboplatin (AUC 5, day 2)
Number of subjects: 5
Study: 2010565

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (8 g for 21 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Olive oil (identical-looking capsules for 21 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg single dose)
Number of subjects: 12
Study: 7124629

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg 3 times daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg 3 times daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31957468

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 31477157

Group type: EXPERIMENTAL
Intervention: SMART WASHOKU meal
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 21